Ross Abrams to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Ross Abrams has written about Antimetabolites, Antineoplastic.
Connection Strength
1.266
-
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):809-16.
Score: 0.395
-
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg. 2007 Mar; 142(3):285-8.
Score: 0.301
-
Management of a patient with borderline resectable pancreatic cancer. Case report and review. Oncology (Williston Park). 2008 Nov 30; 22(13):1524-9.
Score: 0.085
-
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009 Jan; 136(1):187-95.
Score: 0.084
-
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 05; 299(9):1019-26.
Score: 0.081
-
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):178-82.
Score: 0.075
-
Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? Int J Radiat Oncol Biol Phys. 2003; 56(4 Suppl):3-9.
Score: 0.056
-
Adjuvant therapy for pancreatic adenocarcinoma. J Gastrointest Surg. 2001 Jan-Feb; 5(1):6-7.
Score: 0.049
-
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys. 1999 Jul 15; 44(5):1039-46.
Score: 0.044
-
Adjuvant therapy for pancreatic cancer: back to the future. Int J Radiat Oncol Biol Phys. 1998 Aug 01; 42(1):59-63.
Score: 0.041
-
Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 =90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e291-7.
Score: 0.027
-
A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):965-6.
Score: 0.016
-
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):19-27.
Score: 0.012